drugset
drugset / Trial / NCT05218629

Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer

NCT05218629 ↗

Phase 2 Unknown 20 enrolled Qingdao Central Hospital
NaSingle-groupOpen-labelTreatment

Summary

This research study is a Phase 2 clinical trial. It will test the efficiency and safety of an investigational drug of Anlotinib (a small molecular anti-VEGF TKI) with PD-1 inhibitor in second-line therapy with the goal of determining the OS of metastatic pancreatic adenocarcinoma. Subjects must have a stage 4 untreated metastatic pancreatic ductal cancer failed to first-line chemotherapy and meet all inclusion/exclusion criteria. Treatment consists of treatment with anlotinib 8-12 mg oral, day 1-14, and PD-1 inhibitor 200 mg iv, every 21 days each cycle. Treatment will be administered until untolerable toxicities or progression or subject death, or either the subject or sponsor discontinues the study.

Timeline

Start
2022-01-01
Primary completion
2024-12-31
Completion
2025-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 8 mg Oral
Subject Catequentinib Small molecule 12 mg Oral
Subject Catequentinib Small molecule 14 mg Oral
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

No indication recorded.